Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
116.60
+0.05 (+0.04%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
8,368,161
Open
116.80
Bid (Size)
116.30 (4)
Ask (Size)
116.62 (1)
Prev. Close
116.55
Today's Range
115.92 - 116.81
52wk Range
99.14 - 134.63
Shares Outstanding
2,531,374,696
Dividend Yield
2.50%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
August 24, 2024
Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with...
Via
Talk Markets
MarketBeat Week in Review – 8/19 - 8/23
August 24, 2024
Stocks closed the week higher on the near certainty that the Fed will cut interest rates in September, but in the short term, all eyes are on NVDA earnings
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Performance
YTD
+2.97%
+2.97%
1 Month
-7.35%
-7.35%
3 Month
-7.53%
-7.53%
6 Month
-9.50%
-9.50%
1 Year
+5.80%
+5.80%
More News
Read More
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
August 23, 2024
Via
Benzinga
Exposures
Product Safety
Merck's Ebola Vaccine Showed 84% Effectiveness During Large Outbreak In Africa
August 22, 2024
Via
Benzinga
Merck & Co's Options: A Look at What the Big Money is Thinking
August 19, 2024
Via
Benzinga
In-Depth Analysis: Merck & Co Versus Competitors In Pharmaceuticals Industry
August 14, 2024
Via
Benzinga
Uncovering Dividend Opportunities with NYSE:MRK.
August 09, 2024
Via
Chartmill
Big Pharma Stocks: Who’s Leading The Race And Who’s Slipping?
August 20, 2024
Via
Talk Markets
Biotech Bull Market: 3 Ways To Play It
August 20, 2024
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
August 20, 2024
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
August 19, 2024
Via
MarketBeat
Exposures
COVID-19
Product Safety
Looking Into Merck & Co's Recent Short Interest
August 08, 2024
Via
Benzinga
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
August 18, 2024
Via
The Motley Fool
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
August 15, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
August 15, 2024
Via
Investor's Business Daily
2 Dow Jones Stocks to Buy Hand Over Fist Right Now
August 15, 2024
Via
The Motley Fool
Topics
Economy
Stocks
Exposures
Economy
US Equities
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
August 14, 2024
Via
InvestorPlace
9 Health Care Stocks Whale Activity In Today's Session
August 13, 2024
Via
Benzinga
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
August 09, 2024
Via
Benzinga
'I'm Not Proud Of Myself': Jim Cramer Says He Bought 'Worst Of The Three' GE Stocks
August 09, 2024
Via
Benzinga
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
August 09, 2024
From
Merck & Co., Inc.
Via
Business Wire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
August 08, 2024
Via
Investor Brand Network
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
August 08, 2024
Via
Benzinga
Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer
August 08, 2024
From
Merck & Co., Inc.
Via
Business Wire
The 3 Best Biotech Stocks to Buy in August 2024
August 08, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.